Introduction
Cryptococcosis is an opportunistic fungal infection caused by Cryptococcus neoformans or Cryptococcus gattii . The latter is more prevalent in immunocompetent individuals, while infections by C. neoformans mainly affect immunocompromised patients [1, 2] .
C. neoformans strains must be updated. Our study analyzes the agents causing cryptococcosis over the last 18 years in a large teaching institution. We assess the phenotypic and genotypic characteristics and antifungal susceptibility profi les of the strains.
Materials and methods

Episodes, patients, and C. neoformans isolates
From 1990 to 2007, we detected 70 episodes of cryptococcosis in 68 different patients in our hospital. Episodes were considered different when the isolation of Cryptococcus spp. was separated by Ͼ 3 months. We analyzed a subset of 56 episodes (55 patients) for which isolates were available. Cryptococcosis presented as meningitis ( n ϭ 24), fungemia ϩ meningitis ( n ϭ 21), and fungemia alone ( n ϭ 11). The underlying conditions of the patients were classifi ed as HIV infection ( n ϭ 48) or non-HIV-related immunodefi ciency ( n ϭ 7). The patients with non -HIVrelated immunodefi ciency had received solid organ transplants ( n ϭ 4; three renal transplant recipients and one heart transplant recipient) or had other immunosuppressive conditions ( n ϭ 3; one HCV cirrhosis, one rheumatoid arthritis under immunosuppressive therapy with corticosteroids, methotrexate, and infl iximab and one systemic lupus erythematosus and alveolar proteinosis).
A total of 95 available C. neoformans strains from 55 patients were studied. Samples from patients were taken when clinically indicated. Only one colony from each plate was stored. The number of strains per patient was not homogeneously distributed, i.e., 35 patients had only one strain, nine patients had two strains, six patients had three strains, three patients had four strains and two patients had six strains. The Cryptococcus spp. strains were stored at -70ºC in tubes containing sterile distilled water. To ensure viability and purity, each isolate was subcultured on sheep blood agar (Soria Melguizo, Madrid, Spain) before analysis. In patients with multiple isolates available from the same episode, only the fi rst strain of each genotype was selected (58 isolates).
Genotyping, serotyping, and mating-typing
The Cryptococcus strains were analyzed for their mating-, sero-, and genotypes, as well as their in vitro antifungal susceptibilities. All available strains from each patient were genotyped in order to detect co-existence of different genotypes in a single episode. The mating-types and serotypes of the strains were determined using four different polymerase chain reactions (PCRs) that specifi cally amplify the STE20 a and STE20 α locus of either serotype A and D isolates (9). Amplifi ed fragment length polymorphism (AFLP) fi ngerprint analysis was carried out to determine the genotypes of all C. neoformans isolates [7, 8] . The strains CBS8710 (AFLP1/VNI; alphaA), CBS9172 (AFLP1/VNI; a A), CBS10511 (AFLP2/VNIV; alphaD), CBS10513 (AFLP2/VNIV; a D), CBS10078 (AFLP4/VGI; alphaB), CBS10080 (AFLP3/VNIII; alphaA a D), CBS10081 (AFLP5/ VGIII; alphaB), CBS10082 (AFLP6/VGII; alphaB), and CBS10101 (AFLP7/VGIV; alphaC) were included as quality control strains for mating-, sero-, and genotyping. A dendrogram was calculated using single linkage clustering in combination with the Pearson correlation using Bionumerics version 4.6.1 (Applied Maths, Sint-Martens-Latem, Belgium).
Antifungal susceptibility testing procedures
A total of 58 strains were available for antifungal susceptibility testing. We used the antifungal agents obtained as reagent-grade powders from their respective suppliers. The panel of fi ve antifungal agents included amphotericin B (Sigma Chemical Co., Madrid, Spain), fl uconazole, voriconazole (Pfi zer Pharmaceutical Group, New York, New York, USA), isavuconazole (Basilea Pharmaceutica Ltd, Basel, Switzerland), and posaconazole (Schering-Plough Research Institute, Kenilworth, New Jersey, USA). Antifungal activity was determined using the CLSI M27-A3 broth microdilution procedure [10] .
The fi nal concentrations for each antifungal agent were as follows; amphotericin B, posaconazole, isavuconazole, and voriconazole, 0.031 μ g/ml to 32 μ g/ml; and fl uconazole, 0.062 μ g/ml to 64 μ g/ml. No precipitates were observed for concentrations of posaconazole above 8 μ g/ml.
Although the CLSI M27-A3 procedure recommends that inocula be prepared after growing strains on Sabouraud dextrose agar or potato dextrose agar, we cultured the Cryptococcus neoformans isolates on sheep blood agar for 48 -72 h at 35ºC to improve growth. All the inoculated trays were incubated at 35ºC and read macroscopically at 72 h. The MIC endpoint for amphotericin B was defi ned as the lowest concentration that produced complete inhibition of growth (MIC-0), whereas for the remaining agents it was defi ned as the lowest concentration at which a signifi cant decrease in turbidity, corresponding to approximately 50% inhibition of growth, was observed (MIC-2) [10] .
The same batch of trays was used to assess antifungal susceptibility. Quality control was ensured by testing Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019, and all results were within the recommended CLSI limits. The activity of the fi ve antifungal agents was shown as the MIC 90 , MIC 50 , and range of MICs.
Data analysis. We analyzed the correlation between the presence of a specifi c different mating-type, serotype, or genotype of C. neoformans , and the predisposing conditions of the patients or their sex (Fisher exact test). The activity of the fi ve antifungal agents was shown as the cumulative percentage of isolates in each MIC and geometric mean (GM). For calculation of GM, MICs below the lowest antifungal concentration were considered 0.015 μ g/ml (for the new triazoles). We analyzed the differences in the GM of the MICs of the antifungal agents against the strains grouped by mating-type, serotype, and genotype, and predisposing condition (HIV infection or other immunosuppressive conditions). The null hypothesis was rejected in every hypothesis contrast for an alpha error below 0.05. Tables 1 and 2 and Fig. 1 show the distribution of serotypes, mating-types, and genotypes of the 58 isolates causing the 56 episodes of cryptococcosis. Serotype A ( n ϭ 34; 58.9%) predominated, although serotype AD was involved in 23.2% of the episodes. The mating-type analysis revealed that most of the episodes were caused by α ( n ϭ 41; 73.2%) or α / a strains ( n ϭ 12; 21.5%). One episode was caused by a C. neoformans isolate that was non-typeable for mating-type and serotype, but was identifi ed based on AFLP genotyping as AFLP1B, corresponding to C. neoformans var. grubii .
Results
Mating-, sero-, and genotyping
The most widely distributed AFLP genotype was AFLP1 ( n ϭ 26; 46.4%), followed by AFLP3 ( n ϭ 21; 37.5%) and AFLP2 ( n ϭ 11; 19.6%). In 35 episodes (35 patients), only one available isolate was analyzed and no genetic diversity was identifi ed. However, in the remaining 21 episodes (20 patients) we were able to analyze two or more strains per episode, and this allowed us to demonstrate the coexistence of different serotypes and/or genotypes in the same episode in two different patients. One HIV-infected patient had an episode caused by two different C. neoformans genotypes (AFLP1 and 3); this was consistent with the results of the mating-type and serotype analyses (two α A strains were isolated from cerebrospinal fl uid and blood, and one α A-a D strain was isolated from a cerebrospinal fl uid sample taken 3 weeks later). Another HIVinfected patient also had an episode caused by two different genotypes (an AFLP1B and an AFLP3 strain, both isolated from cerebrospinal fl uid samples taken 15 days apart from each other).
In our hospital, episodes of cryptococcosis were caused by C. neoformans var. grubii ( n ϭ 24; 42.9%), C. neoformans var. neoformans ( n ϭ 11; 19.6%), the hybrid C. neoformans var. grubii ϫ C. neoformans var. neoformans ( n ϭ 19; 33.9%), and the co-existence of both C. neoformans var. grubii and the hybrid C. neoformans var. grubii ϫ C. neoformans var. neoformans ( n ϭ 2; 3.6%). One strain was non-typeable and two episodes were caused by a combination of the A and AD serotypes.
2 Two episodes were caused by a combination of the α and α/a mating-types.
Twenty-two strains belonged to genotype AFLP3, of which 13 were serotype AD by PCR analysis and only the serotype A background could be determined with the remaining nine strains. AD hybrids may become aneuploid, with the result that the full serotype AD background is no longer present in the genomic DNA of these isolates.
Relationship between strain characteristics (mating-type, serotype, and genotype), underlying conditions, and sex
We could not fi nd a specifi c mating-type or serotype that was more prevalent in HIV-infected patients than in patients with non-HIV-related immunodefi ciency. However, we found that AFLP genotypes 1, 1A, and 1B were more prevalent in HIV-infected patients ( P ϭ 0.034) ( Table 2) . Serotype A and AFLP genotypes 1, 1A, and 1B were more prevalent in females, whereas AFLP genotype 3 was more prevalent in males ( P Ͻ 0.05) ( Table 2) . Table 3 summarizes the antifungal susceptibility results of the 58 strains involved in the 56 episodes of cryptococcosis. The new triazoles, i.e., voriconazole, posaconazole, and isavuconazole showed high and similar antifungal activity -all strains had a MIC Յ 0.125 μ g/ml. Fluconazole also had good antifungal activity -only two strains from HIV-infected patients had an MIC of 16 μ g/ml (3.4%) and both remained highly susceptible to the three new triazoles (MICs Յ 0.062 μ g/ml). The remaining strains always showed MICs Յ 8 μ g/ml. Only two strains showed an MIC Ͼ 1 μ g/ml for amphotericin B.
Antifungal susceptibility testing results
We did not fi nd differences in antifungal susceptibility between strains isolated from HIV-infected patients and non-HIV-infected patients.
We compared the geometric mean of the MICs of each antifungal agent against isolates grouped by serotype, mating type and AFLP genotype. Isolates belonging to serotype A showed signifi cantly higher MICs (0.937 μ g/ml) for amphotericin B than those from serotype D (0.818 μ g/ml) and serotype AD (0.692 μ g/ml) ( P Ͻ 0.01). Isolates belonging to AFLP type 1, 1A, and 1B were less susceptible for amphotericin B (0.981 μ g/ml) than AFLP type 3 (0.725 μ g/ ml) ( P Ͻ 0.05).
No differences in susceptibility to the new triazoles were observed for the different serotypes, mating types, and genotypes of C. neoformans studied.
Discussion
Our study evaluated the epidemiology of C. neoformans in a single institution over a period of 18 years. Cryptococcosis patients admitted to our hospital were infected mainly by C. neoformans var. grubii (genotype AFLP1). However, a high proportion of episodes were caused by serotype AD (23.2%) strains. Many clinical C. neoformans isolates from Italy, Spain, Portugal, and Greece have been shown to be serotype AD, thus suggesting a high incidence of serotype AD hybrids in southern Europe [11] .
AFLP genotyping was employed with all Cryptococcus spp. strains recovered from patients to identify their variety within the C. neoformans complex, and to confi rm the serotyping analysis based on four different PCRs. Serotyping based on PCR alone may lead to incorrect identifi cations due to the fact that diploid isolates (e.g., serotype AD hybrids) can become aneuploid and lose parts of their genomic content, including regions containing the target for the serotype PCRs. This was observed in some of the C. neoformans strains studied and may explain the discrepancy between PCR-based serotyping (58.9% episodes caused by serotype A strains and 23.2% of the episodes by serotype AD strains) and AFLP genotyping, i.e., 46.4% of the episodes caused by AFLP1 strains and 37.5% of the episodes by genotype AFLP3 strains. The presence of two or more different genotypes of C. neoformans causing a single episode of cryptococcosis has been poorly evaluated. The presence of several genotypes can only be detected when more than one sample is analyzed from the same patient. In this study, 21 episodes (20 patients) of cryptococcosis yielded at least two isolates from different samples. Although we only stored one colony from each sample, we were able to show that two of the episodes were caused by two different AFLP genotypes, suggesting that cryptococcosis can be a co-infection of multiple C. neoformans genotypes. There are few reports of infections caused by multiple-genotype C. neoformans isolates. Haynes et al . [12] described the involvement of different C. neoformans genotypes in recurrent cryptococcosis, which was explained by the fact that either the patient was re-infected with a distinguishable C. neoformans strain during and/or after antifungal treatment, or that one of the strains causing the primary infection was more persistent than the other. Another explanation is that the karyotype became unstable during infection. This phenomenon was reported by Fries et al . [13] , who observed that chromosomal arrangements and/or deletions took place in a murine model. However, it seems unlikely that the karyotype became unstable in the mixed infections described as it implies that the strain with the hybrid genotype AFLP3 (serotype AD) has lost approximately half of its genetic content during the infection to become a strain with genotype AFLP1 (serotype A). Therefore, a mixed infection with two different genotypes of C. neoformans seems to be the most plausible explanation.
Although several studies have evaluated the antifungal susceptibility of C. neoformans and C. gattii [2,14 -18] , the introduction of new drugs means that data on antifungal susceptibility should be updated. We found a low rate of resistance to fl uconazole in our 58 C. neoformans isolates. There is some evidence that the MICs of fl uconazole ( Ն 16 μ g/ml) and amphotericin B ( Ն 2 μ g/ml) against C. neoformans can be a predictor of poor patient outcomes in cases of cryptococcosis [19 -21] . Therefore, all isolates in the present study were classifi ed as susceptible to amphotericin B, and 3.6% were fl uconazole-resistant ( Ն 16 μ g/ml). The higher MICs of amphotericin B of some serotypes or genotypes may not have any clinical consequences. No history of treatment with fl uconazole could be demonstrated in the two patients with isolates showing an MIC of 16 μ g/ml for fl uconazole. Although some authors found a low level of fl uconazole resistance in C. neoformans when analyzing a large number of clinical strains [22 -24] , others reported an increasing proportion of resistant strains [25] . Interestingly, Perkins et al . [26] reported in 2005 that 46.6% ( Ն 16 μ g/ml) of the strains in a collection comprising 317 clinical isolates of C. neoformans var. neoformans from a Spanish mycology reference laboratory were fl uconazole-resistant. This proportion of fl uconazole-resistant C. neoformans strains is considerably higher than that observed in the present study (3.6%) and by other Spanish investigators [27] . The discrepancies may be explained by variations in the antifungal susceptibility testing procedure (EUCAST vs. CLSI) and a bias in the selection of strains submitted to the reference laboratory.
The new triazoles studied (voriconazole, posaconazole, and isavuconazole) showed potent antifungal activity against all the evaluated strains, with MICs Յ 0.125 μ g/ ml. These fi ndings are consistent with previous reports [27 -31] .
In conclusion, we found that most cases of cryptococcosis in our hospital were caused by strains of C. neoformans , with a predominance of C. neoformans var. grubii . The C. neoformans isolates showed a low level of resistance to fl uconazole, and were highly susceptible to the new triazoles, including isavuconazole.
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